The implementation of nanomedicine in cellular, preclinical, and clinical studies has led to
exciting advances ranging from fundamental to translational, particularly in the field of …

Both communicable and non-communicable chronic respiratory conditions have accorded
for suffering of millions of people of all ages and stated to be leading cause of death …

Efficacy and safety of tiotropium+ olodaterol fixed-dose combination (FDC) compared with
the mono-components was evaluated in patients with moderate to very severe chronic …

Background Treatment guidelines recommend the use of inhaled long-acting
bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with …

Background Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in
development for chronic obstructive pulmonary disease (COPD). The efficacy and safety of …

Introduction We report the results of the first direct comparison of the once-daily fixed-dose
long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) combinations …

Background The combination of aclidinium bromide, a long-acting anticholinergic, and
formoterol fumarate, a long-acting beta 2-agonist (400/12 μg twice daily) achieves …

Background Long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)
combinations are a treatment option for patients with COPD who continue to have symptoms …

Background This study investigated the effects on 24-h lung function and lung volume of a
once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium …

Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
Phase III studies investigated the long-term efficacy and safety of once-daily olodaterol via …